Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 275 Carcinoma, Intraductal, Noninfiltrating 25 Breast Carcinoma In Situ 21 Neoplasm Metastasis 14 Neoplasms 13 Breast Neoplasms, Male 12 Ovarian Neoplasms 10 Inflammatory Breast Neoplasms 7 Glioblastoma 6 Endometrial Neoplasms 6 Prostatic Neoplasms 5 Central Nervous System Neoplasms 5 Gliosarcoma 4 Fallopian Tube Neoplasms 4 Breast Cancer Female 4 Brain Neoplasms 4 Recurrence 3 Obesity 3 Hot Flashes 3 Glioma 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Ductal, Breast 3 Breast Diseases 3 Astrocytoma 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Sleep Wake Disorders 2 Sarcoma 2 Pancreatic Neoplasms 2 Oligodendroglioma 2

Interventions

lutetium Lu 177 dotatate 40 Everolimus 35 Magnetic Resonance Spectroscopy 15 lanreotide 14 gallium Ga 68 dotatate 13 Temozolomide 13 Octreotide 12 Nivolumab 12 pembrolizumab 11 Capecitabine 11 surufatinib 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 cabozantinib 9 Positron Emission Tomography Computed Tomography 9 3-Iodobenzylguanidine 9 Sunitinib 8 Specimen Handling 7 Carboplatin 7 telotristat ethyl 6 pasireotide 6 amino-acid, glucose, and electrolyte solution 6 Somatostatin 6 Lutetium-177 6 90Y-octreotide, DOTA-Tyr(3)- 6 lenvatinib 5 Ipilimumab 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 Etoposide 5 Cisplatin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Tamoxifen × Clear all

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡